Back to Search Start Over

Impaired Cellular Immunity to SARS-CoV-2 in Severe COVID-19 Patients.

Authors :
Ni, Ling
Cheng, Meng-Li
Feng, Yu
Zhao, Hui
Liu, Jingyuan
Ye, Fang
Ye, Qing
Zhu, Gengzhen
Li, Xiaoli
Wang, Pengzhi
Shao, Jing
Deng, Yong-Qiang
Wei, Peng
Chen, Fang
Qin, Cheng-Feng
Wang, Guoqing
Li, Fan
Zeng, Hui
Dong, Chen
Source :
Frontiers in Immunology; 2/2/2021, Vol. 11, pN.PAG-N.PAG, 10p
Publication Year :
2021

Abstract

The high infection rate and rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) make it a world-wide pandemic. Individuals infected by the virus exhibited different degrees of symptoms, and most convalescent individuals have been shown to develop both cellular and humoral immune responses. However, virus-specific adaptive immune responses in severe patients during acute phase have not been thoroughly studied. Here, we found that in a group of COVID-19 patients with acute respiratory distress syndrome (ARDS) during hospitalization, most of them mounted SARS-CoV-2-specific antibody responses, including neutralizing antibodies. However, compared to healthy controls, the percentages and absolute numbers of both NK cells and CD8<superscript>+</superscript> T cells were significantly reduced, with decreased IFNγ expression in CD4<superscript>+</superscript> T cells in peripheral blood from severe patients. Most notably, their peripheral blood lymphocytes failed in producing IFNγ against viral proteins. Thus, severe COVID-19 patients at acute infection stage developed SARS-CoV-2-specific antibody responses but were impaired in cellular immunity, which emphasizes on the role of cellular immunity in COVID-19. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
16643224
Volume :
11
Database :
Complementary Index
Journal :
Frontiers in Immunology
Publication Type :
Academic Journal
Accession number :
148481749
Full Text :
https://doi.org/10.3389/fimmu.2021.603563